Our Approach
Our Approach
Our Approach
About Us
Latest news update:
Atorvia awarded inaugural Blue Ticket, sponsored by Merck, at new SpinUp lab at University of Toronto. Read more here.
Atorvia awarded inaugural Merck-sponsored Blue Ticket at SpinUp labs
Generous support from Merck* provides mentorship and one year SpinUp membership at the University of Toronto's brand new state-of-the-art labs space on the Mississauga campus.
*Known as MSD outside Canada and the US
Atorvia selected as start-up pitch finalist for Effervescence 2024
Atorvia accepted into the OBIO Women in Health Initiative (WiHI) seed program
As a majority woman owned and woman led life sciences company in Ontario, we proudly acknowledge the support of OBIO and the Federal Government of Canada and are delighted to be participating in the WiHI program.
Atorvia accepted into the Creative Destruction Labs program
We are thrilled to announce that Atorvia will participate as one of the Ventures at the CDL-Berlin accelerator program in the 2023/24 Health Stream cohort as we take another important step on our journey to #BuildSomethingMassive and revolutionize treatment for organ failure, beginning with a kidney franchise initially targeting Acute Kidney Injury.
Read more about the program here:
We are pleased to announce Atorvia will be one of the 20 companies pitching at MassBio Align Summit w/ insights by McKinsey & Company. The day will include keynotes, panel discussions, and pitches from other innovative seed/series A #biotech, #healthtech, and #medtech start-ups. Plus, attendees will have the opportunity to set up their own 1:1 partnering meetings with investors throughout the day. #AlignSummit
Register to hear our pitch here: https://lnkd.in/egWgFdcR
Atorvia to present at MassBio Align Summit
Atorvia to present at McKinsey ESIC 2022
Come meet us at McKinsey's #ESIC2022 Conference on June 23rd and learn more about the work we are doing to develop new and life-saving technologies for patients with organ failure, with our first program in Acute Kidney Injury.
MassBio Accelerator S22
Atorvia successfully graduated from the prestigious #Massbio accelerator program, #MassBioDrive spring 2022 cohort, one of only 7% of companies applying to be accepted into the program.
Learn more about MassBioDrive and the spring 2022 cohort here: https://bit.ly/360dHLj
